Apidra 2015 report
Apidra 2015 U.S. PROMOTIONAL AUDIT REPORT
Published July 2016 • 22 Pages
The 5 Key Questions Addressed by this Report:
- How many physicians were reached by Apidra through personal promotion in 2015 and how does this compare to its peer set in the Type 1 Diabetes – Insulin and Type 2 Diabetes – Insulin markets?
- What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
- How does Sanofi’s depth of coverage vary within key specialties (e.g., Internal Medicine, Family Medicine, and Endocrinology) and how does this compare to its peers and the overall set of rep-accessible physicians?
- How often are physicians receiving paid meals for Apidra throughout the year (e.g., monthly, quarterly, annually)?
- Who were the most detailed prescribers and top paid speakers/consultants for Apidra in 2015?
Data Sources and Methodology:
- MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
- Over 9,000 paid interactions across 5,800 physicians made on behalf of Apidra were carefully examined to support our analysis. In addition, interaction data from 8 peer products (e.g. Afrezza, Humalog, Humulin, Lantus, Levemir, NovoLog, Toujeo, and Tresiba) was leveraged to provide benchmarking and market insights.